Introduction
Bioavailability refers to the fraction of an administered compound that reaches systemic circulation in an active form. For research peptides, route of administration is one of the most important variables affecting bioavailability, and selecting the appropriate route is critical for research protocol design. This guide explains why peptides present unique bioavailability challenges and how different administration routes address them.
Why Oral Bioavailability Is Poor for Most Peptides
The gastrointestinal tract presents a formidable barrier to peptide absorption. Peptides are chains of amino acids connected by peptide bonds, and the GI tract is specifically designed to cleave these bonds through the action of proteolytic enzymes including pepsin in the stomach and various peptidases in the small intestine. Most peptides are substantially or completely degraded before they can be absorbed intact. Additionally, even if a peptide survives GI proteolysis, the intestinal epithelium presents a permeability barrier that large hydrophilic molecules cannot easily cross. The result is that most research peptides have very low or negligible oral bioavailability.
Subcutaneous Administration
Subcutaneous injection — delivery into the tissue layer between the skin and muscle — is the most common research administration route for peptides. Bioavailability following subcutaneous injection typically ranges from 70% to near 100% for most peptides, as the compound is deposited directly into vascularized tissue where it can be absorbed into the bloodstream without first-pass metabolism. Absorption is typically slower than intravenous administration, providing more gradual entry into circulation.
Intravenous Administration
Intravenous administration delivers 100% bioavailability by definition, as the compound enters systemic circulation directly. It produces rapid peak concentrations and is used in research when precise timing of peptide delivery relative to a measured endpoint is required. IV administration is more technically demanding and less practical for repeated-dose protocols in animal models.
Intramuscular Administration
Intramuscular injection provides bioavailability comparable to subcutaneous delivery for most peptides, with absorption rate depending on muscle vascularity and the formulation. It is less commonly used than subcutaneous administration for research peptides but is appropriate for some protocols.
Intranasal Administration
Intranasal delivery has attracted research interest for neuropeptides due to the potential for direct nose-to-brain transport via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier. Selank and Semax have been studied extensively via intranasal routes in Russian clinical research. Bioavailability to systemic circulation via intranasal delivery is moderate but direct CNS delivery efficiency may be significant for certain compounds.
Oral Peptide Research
Research into orally bioavailable peptides is an active field focused on strategies to protect peptides from GI degradation, including cyclization, D-amino acid substitution, PEGylation, nanoparticle encapsulation, and permeation enhancers. BPC-157 is unusual among research peptides in being studied for oral bioavailability, with animal research suggesting meaningful activity following oral administration attributed to its stability in gastric juice.
Conclusion
Route of administration is a critical variable in peptide research design. Subcutaneous injection is the standard research route for most compounds due to its high bioavailability, practical simplicity, and compatibility with repeated-dose protocols. Understanding the bioavailability profile of each administration route ensures that observed research effects reflect the intended compound exposure.